Mein Warenkorb

ICOS

ICOS Molekülinformation

Englischer NameInducible T-cell costimulatorAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel7Target-AliasActivation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameInducible T-cell costimulator
Target-AliasActivation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel7
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

ICOS Produktliste

  • Attribut

    Protein (6)

  • Produktbibliothek

    Online (6)

  • Spezies

    Human (3)Mouse (2)Rat (1)

  • Etikett

    His Tag & Avi Tag (1)Fc Tag (2)His Tag (3)

  • Marker

    Biotin-labeled (1)Unconjugated (5)

ICOS Molekülhintergrund

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS Molekülalias

ICOS,CD278,AILIM,Inducible T-cell costimulator

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
VopratelimabJTX-2011Phase 2 ClinicalJounce Therapeutics IncNeoplasms; Carcinoma, Non-Small-Cell Lung
Details
FeladilimabGSK-609; GSK-3359609Phase 2 ClinicalGlaxosmithkline PlcHead and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma
Details
AcazicolceptALPN-101Phase 2 ClinicalAlpine Immune Sciences IncGraft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation
Details
MEDI-570Phase 1 ClinicalJapan Tobacco (Hong Kong) LtdLymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides
Details
IzuralimabXmAb-23104; XmAb-104Phase 1 ClinicalXencor IncTriple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Solid tumours; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell
Details
Anti-ICOS (Bristol Myers Squibb)BMS-986226Phase 1 ClinicalBristol-Myers Squibb CompanyNeoplasms
Details
anti-ICOS mAb (Bristol-Myers Squibb)Phase 1 ClinicalBristol-Myers Squibb CompanySolid tumours; Neoplasms
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns